Completed
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
NCT05323435
- Conditions
- COVID-19, Coronaviridae Infections, Coronavirus Infections, +9 more
- Locations
-
- AI Kuwait Hospital Dubai, United Arab Emirates